Context Therapeutics (CNTX) Expected to Announce Earnings on Thursday

Context Therapeutics (NASDAQ:CNTX) is expected to release its earnings data before the market opens on Thursday, March 20th. Analysts expect Context Therapeutics to post earnings of ($0.05) per share for the quarter.

Context Therapeutics Trading Up 19.2 %

Shares of NASDAQ CNTX opened at $0.84 on Tuesday. The firm has a 50 day moving average of $0.88 and a 200 day moving average of $1.47. The firm has a market capitalization of $63.11 million, a price-to-earnings ratio of -0.92 and a beta of 2.06. Context Therapeutics has a 12-month low of $0.64 and a 12-month high of $2.75.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CNTX. Citizens Jmp upgraded shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. JMP Securities initiated coverage on shares of Context Therapeutics in a research report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price target for the company. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a research report on Wednesday, January 15th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $6.33.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.